103 related articles for article (PubMed ID: 28422250)
1. A novel nanomissile targeting two biomarkers and accurately bombing CTCs with doxorubicin.
Gao Y; Xie X; Li F; Lu Y; Li T; Lian S; Zhang Y; Zhang H; Mei H; Jia L
Nanoscale; 2017 May; 9(17):5624-5640. PubMed ID: 28422250
[TBL] [Abstract][Full Text] [Related]
2. Neovasculature and circulating tumor cells dual-targeting nanoparticles for the treatment of the highly-invasive breast cancer.
Yao J; Feng J; Gao X; Wei D; Kang T; Zhu Q; Jiang T; Wei X; Chen J
Biomaterials; 2017 Jan; 113():1-17. PubMed ID: 27794222
[TBL] [Abstract][Full Text] [Related]
3. EpCAM aptamer-functionalized mesoporous silica nanoparticles for efficient colon cancer cell-targeted drug delivery.
Xie X; Li F; Zhang H; Lu Y; Lian S; Lin H; Gao Y; Jia L
Eur J Pharm Sci; 2016 Feb; 83():28-35. PubMed ID: 26690044
[TBL] [Abstract][Full Text] [Related]
4. In vivo inhibition of circulating tumor cells by two apoptosis-promoting circular aptamers with enhanced specificity.
Dong H; Han L; Wang J; Xie J; Gao Y; Xie F; Jia L
J Control Release; 2018 Jun; 280():99-112. PubMed ID: 29746957
[TBL] [Abstract][Full Text] [Related]
5. In vivo distribution and antitumor activity of doxorubicin-loaded N-isopropylacrylamide-co-methacrylic acid coated mesoporous silica nanoparticles and safety evaluation.
Chen Y; Yang W; Chang B; Hu H; Fang X; Sha X
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):406-12. PubMed ID: 23816639
[TBL] [Abstract][Full Text] [Related]
6. Enrichment and Viability Inhibition of Circulating Tumor Cells on a Dual Acid-Responsive Composite Nanofiber Film.
Wang W; Cheng Y; Li Y; Zhou H; Xu LP; Wen Y; Zhao L; Zhang X
ChemMedChem; 2017 Apr; 12(7):529-536. PubMed ID: 28229535
[TBL] [Abstract][Full Text] [Related]
7. Redox-responsive mesoporous selenium delivery of doxorubicin targets MCF-7 cells and synergistically enhances its anti-tumor activity.
Zhao S; Yu Q; Pan J; Zhou Y; Cao C; Ouyang JM; Liu J
Acta Biomater; 2017 May; 54():294-306. PubMed ID: 28267598
[TBL] [Abstract][Full Text] [Related]
8. Dual targeting mesoporous silica nanoparticles for inhibiting tumour cell invasion and metastasis.
Li W; Guo Z; Zheng K; Ma K; Cui C; Wang L; Yuan Y; Tang Y
Int J Pharm; 2017 Dec; 534(1-2):71-80. PubMed ID: 28958879
[TBL] [Abstract][Full Text] [Related]
9. Negative-charge-functionalized mesoporous silica nanoparticles as drug vehicles targeting hepatocellular carcinoma.
Xie M; Xu Y; Shen H; Shen S; Ge Y; Xie J
Int J Pharm; 2014 Oct; 474(1-2):223-31. PubMed ID: 25149125
[TBL] [Abstract][Full Text] [Related]
10. One-pot synthesis of sustained-released doxorubicin silica nanoparticles for aptamer targeted delivery to tumor cells.
He X; Hai L; Su J; Wang K; Wu X
Nanoscale; 2011 Jul; 3(7):2936-42. PubMed ID: 21623439
[TBL] [Abstract][Full Text] [Related]
11. The Architecture and Function of Monoclonal Antibody-Functionalized Mesoporous Silica Nanoparticles Loaded with Mifepristone: Repurposing Abortifacient for Cancer Metastatic Chemoprevention.
Gao Y; Gu S; Zhang Y; Xie X; Yu T; Lu Y; Zhu Y; Chen W; Zhang H; Dong H; Sinko PJ; Jia L
Small; 2016 May; 12(19):2595-608. PubMed ID: 27027489
[TBL] [Abstract][Full Text] [Related]
12. Biodegradable polymeric micelle-encapsulated doxorubicin suppresses tumor metastasis by killing circulating tumor cells.
Deng S; Wu Q; Zhao Y; Zheng X; Wu N; Pang J; Li X; Bi C; Liu X; Yang L; Liu L; Su W; Wei Y; Gong C
Nanoscale; 2015 Mar; 7(12):5270-80. PubMed ID: 25721713
[TBL] [Abstract][Full Text] [Related]
13. Dual-stimuli responsive hyaluronic acid-conjugated mesoporous silica for targeted delivery to CD44-overexpressing cancer cells.
Zhao Q; Liu J; Zhu W; Sun C; Di D; Zhang Y; Wang P; Wang Z; Wang S
Acta Biomater; 2015 Sep; 23():147-156. PubMed ID: 25985912
[TBL] [Abstract][Full Text] [Related]
14. Optical imaging and anticancer chemotherapy through carbon dot created hollow mesoporous silica nanoparticles.
Kang MS; Singh RK; Kim TH; Kim JH; Patel KD; Kim HW
Acta Biomater; 2017 Jun; 55():466-480. PubMed ID: 28373086
[TBL] [Abstract][Full Text] [Related]
15. S-Nitrosocaptopril prevents cancer metastasis in vivo by creating the hostile bloodstream microenvironment against circulating tumor cells.
Lu Y; Lian S; Ye Y; Yu T; Liang H; Cheng Y; Xie J; Zhu Y; Xie X; Yu S; Gao Y; Jia L
Pharmacol Res; 2019 Jan; 139():535-549. PubMed ID: 30366102
[TBL] [Abstract][Full Text] [Related]
16. Doxorubicin-Bound Albumin Nanoparticles Containing a TRAIL Protein for Targeted Treatment of Colon Cancer.
Thao le Q; Byeon HJ; Lee C; Lee S; Lee ES; Choi YW; Choi HG; Park ES; Lee KC; Youn YS
Pharm Res; 2016 Mar; 33(3):615-26. PubMed ID: 26526555
[TBL] [Abstract][Full Text] [Related]
17. Specific aptamer-conjugated mesoporous silica-carbon nanoparticles for HER2-targeted chemo-photothermal combined therapy.
Wang K; Yao H; Meng Y; Wang Y; Yan X; Huang R
Acta Biomater; 2015 Apr; 16():196-205. PubMed ID: 25596325
[TBL] [Abstract][Full Text] [Related]
18. Mesoporous silica nanoparticles loading doxorubicin reverse multidrug resistance: performance and mechanism.
Shen J; He Q; Gao Y; Shi J; Li Y
Nanoscale; 2011 Oct; 3(10):4314-22. PubMed ID: 21892492
[TBL] [Abstract][Full Text] [Related]
19. Programmed packaging of mesoporous silica nanocarriers for matrix metalloprotease 2-triggered tumor targeting and release.
Zou Z; He X; He D; Wang K; Qing Z; Yang X; Wen L; Xiong J; Li L; Cai L
Biomaterials; 2015 Jul; 58():35-45. PubMed ID: 25941780
[TBL] [Abstract][Full Text] [Related]
20. EGF-modified mPEG-PLGA-PLL nanoparticle for delivering doxorubicin combined with Bcl-2 siRNA as a potential treatment strategy for lung cancer.
Zhang X; Wang Q; Qin L; Fu H; Fang Y; Han B; Duan Y
Drug Deliv; 2016 Oct; 23(8):2936-2945. PubMed ID: 26739487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
